HomeENGLISH MAGAZINELiver cancer: "malignant pathways" are already there in cirrhosis

Liver cancer: “malignant pathways” are already there in cirrhosis

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure — but now a study offers hope of early detection, and targets for new treatments. Published in Frontiers in Cell and Developmental Biology, the results show a dramatic increase in expression of sugar-burning ‘glycolytic’ enzymes in precancerous cirrhotic livers. This increase is associated with a significantly higher risk of developing hepatocellular carcinoma (HCC) — the main type of liver cancer — and could lead to a biomarker which identifies those at risk of malignancy. It is known that almost 90% of all hepatocellular carcinoma cases start with liver cirrhosis. In cirrhosis, chronic damage caused by hepatitis viruses B or C, alcohol, or obesity leads to scarring and formation of regenerative nodules in the liver. High cell turnover in these nodules, with accumulation of genetic damage, can eventually produce cancerous cells. So by pinpointing when cirrhosis progresses to cancer, clinicians could improve early detection and treatment perhaps with new treatments which reverse the transition.

For nearly a century, scientists have recognized that cancer cells shift the way they generate energy. Normally the body obtains energy from macronutrients — sugars, fats, proteins and their intermediaries — primarily using oxygen. But our cells can also extract energy from sugars without using oxygen. This anaerobic process, called glycolysis, produces lactic acid that ‘burns’ our muscles during intense exercise — and is also used by cancers to fuel their rampant growth. Like virtually all cancers, highly-proliferating HCC cells seem to readjust their energy metabolism towards glycolysis, irrespective of oxygen availability. The cause of this shift in glucose metabolism — known as the Warburg effect — remains unknown, but inflammation is thought to play a role. Since cirrhosis is an inflammatory process, the team decided to look at whether the metabolic shift to glycolysis is present already in cirrhotic cells — and whether this predicts progression to hepatocellular carcinoma. They analyzed normal, cirrhotic and cancerous (HCC) liver samples from patients followed up over 10 years following a liver biopsy. To have a complete overview of energy metabolism changes in HCC and premalignant stages of disease, they measured the expression of genes encoding enzymes involved in glycolysis and other metabolic pathways.

They found that glycolysis-related genes, like hexokinase 2 (HK2), aldolase A (ALDOA) and pyruvate kinase M2 (PKM2) are highly expressed not only in HCC, but also in cirrhosis as compared to normal liver samples. In other words: the shift to glycolysis occurs in the precancerous stage.  Even more striking, the level of expression of glycolysis-related genes showed positive correlation with progression of cirrhosis to HCC — and with poor outcome in those with HCC already at the time of biopsy. Besides, it is known that nuclear PKM2 acts as a co-activator of β-catenin to induce c-MYC oncogene and glycolytic gene expression, therefore stimulating tumor growth through indirect mechanisms. Moreover, cancer cells facilitate the uptake of glucose and the incorporation of glycolytic metabolites into amino acids, nucleic acids, and lipids. While adapting to these new metabolic needs, the Warburg effect produces increased levels of antioxidant proteins to detoxify reactive oxygen species (ROS). These are responsible for the activation of the stress kinase JNK1 seen in cirrhotic livers and in highly proliferating hepatocarcinomas. In their previous work, the team has noted an existing PKM2-JNK1 axis that could be responsible for the growth advantage. Reduced PKM2 activity allows the accumulation of glucose-6-phosphate, shifting the glucose flux through the pentose phosphate pathway (PPP) to generate NADPH, and consequently reduced glutathione (GSH), the main cellula antioxidant.

Study senior authors Dr. Salvatore Papa of the University of Leeds and Dr. Concetta Bubici of Brunel University London, commented: “This suggests expression of glycolytic enzymes could be used as a new biomarker to predict the risk of later development of HCC in patients with cirrhosis. Further studies are needed to establish whether these changes in gene expression are borne out as changes in glycolytic activity. The shift to a glycolytic expression profile in cirrhotic cells could even be a target for new HCC therapies. For example, clinical trials are currently underway to explore the effect of statins — which are used to help prevent cardiovascular disease — on HCC development in cirrhotic patients or HCC recurrence following surgical removal. It is very likely that by blocking cholesterol synthesis, statins would also suppress glycolysis as these chemical pathways overlap. If these trials show that statins reduce HCC risk, further studies would be necessary to establish whether inhibition of glycolysis in cirrhotic cells is responsible”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Bubici Cet al., Papa S. Front Cell Dev Biol. 2018 Nov.

Papa S, Bubici C. J Hepatol. 2018 Sep; 69(3):572-574. 

Papa S, Bubici C. Mol Cell Oncol. 2016; 3(2):e1103398. 

Iansante V et al., Papa S. Nat Commun. 2015; 6:7882.

The following two tabs change content below.

Dott. Gianfrancesco Cormaci

Medico Chirurgo, Specialista; PhD. a CoFood s.r.l.
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -